BeiGene Revenue 2014-2024 | ONC
BeiGene annual/quarterly revenue history and growth rate from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- BeiGene revenue for the quarter ending September 30, 2024 was $1.002B, a 28.2% increase year-over-year.
- BeiGene revenue for the twelve months ending September 30, 2024 was $3.317B, a 50.46% increase year-over-year.
- BeiGene annual revenue for 2023 was $2.459B, a 73.65% increase from 2022.
- BeiGene annual revenue for 2022 was $1.416B, a 20.37% increase from 2021.
- BeiGene annual revenue for 2021 was $1.176B, a 280.83% increase from 2020.
BeiGene Annual Revenue
(Millions of US $) |
| 2023 |
$2,459 |
| 2022 |
$1,416 |
| 2021 |
$1,176 |
| 2020 |
$309 |
| 2019 |
$428 |
| 2018 |
$198 |
| 2017 |
$238 |
| 2016 |
$1 |
| 2015 |
$9 |
| 2014 |
$13 |
| 2013 |
$11 |
BeiGene Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$1,002 |
| 2024-06-30 |
$929 |
| 2024-03-31 |
$752 |
| 2023-12-31 |
$634 |
| 2023-09-30 |
$781 |
| 2023-06-30 |
$595 |
| 2023-03-31 |
$448 |
| 2022-12-31 |
$380 |
| 2022-09-30 |
$388 |
| 2022-06-30 |
$342 |
| 2022-03-31 |
$307 |
| 2021-12-31 |
$214 |
| 2021-09-30 |
$206 |
| 2021-06-30 |
$150 |
| 2021-03-31 |
$606 |
| 2020-12-31 |
$100 |
| 2020-09-30 |
$91 |
| 2020-06-30 |
$66 |
| 2020-03-31 |
$52 |
| 2019-12-31 |
$57 |
| 2019-09-30 |
$50 |
| 2019-06-30 |
$243 |
| 2019-03-31 |
$78 |
| 2018-12-31 |
$59 |
| 2018-09-30 |
$54 |
| 2018-06-30 |
$53 |
| 2018-03-31 |
$33 |
| 2017-12-31 |
$18 |
| 2017-09-30 |
$220 |
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
$0 |
| 2016-09-30 |
|
| 2016-06-30 |
$0 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$5 |
| 2015-09-30 |
|
| 2015-06-30 |
$1 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
